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Abstract
Objective—To estimate the frequency of unexpected first-trimester ultrasound findings that 
would alter prenatal management in pregnant women eligible for cell-free (cf) DNA screening 
because of advanced maternal age (AMA).
Methods—This was a retrospective cohort study of all AMA women at a tertiary care center who 
had a 10–14-week ultrasound examination between 1 January 2012 and 27 April 2015. 
Information on pregnancy dating, obstetric ultrasound examination, prenatal screening and genetic 
testing were collected from a perinatal database. The primary outcome was an unexpected 
ultrasound finding in the first trimester that would alter the prenatal screening/testing strategy.
Results—In total, 2337 women met the inclusion criteria, with a total of 2462 fetuses. Sixty-
eight (2.9%) women had an anomalous fetus, of which 44 (64.7%) had diagnostic testing. In the 
entire cohort, a non-viable pregnancy was identified in 153 (6.5%) women. Multiple gestation was 
identified in 32 (1.4%) women; five had a cotwin demise. Gestational dating was revised for 126 
(5.4%) women. Among those who opted for aneuploidy screening (n = 1806), 68.5% had cfDNA 
screening and 31.5% had first-trimester screening by analysis of maternal serum biomarkers and 
nuchal translucency thickness. Among those eligible for cfDNA screening, 16.1% (95% CI, 15.0–
18.0%; 377/2337) had an ultrasound finding (anomaly, incorrect dating, multiple gestation, non-
viable pregnancy) at the time of testing that would have altered the provider’s counseling 
regarding the prenatal screening/testing strategy.
Conclusions—A substantial proportion of AMA women eligible for cfDNA screening have fetal 
ultrasound findings that could alter genetic testing strategy and clinical management. This study 
recommends ultrasound examination prior to cfDNA screening in AMA women. Copyright © 
2016 ISUOG. Published by John Wiley & Sons Ltd.
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Non-invasive prenatal screening, using massively parallel sequencing or single-nucleotide 
polymorphism technology to analyze cell-free (cf) DNA fragments in maternal plasma, was 
introduced to clinical settings in the USA in 20111–3. At the time of its introduction, the 
American College of Obstetricians and Gynecologists (ACOG) and the Society for 
Maternal-Fetal Medicine recommended cfDNA screening in women at increased risk of fetal 
aneuploidy4. The new screening paradigm was quickly adopted by providers for high-risk 
patient populations and has significantly reduced the use of alternative screening and 
diagnostic testing in these populations5–8.
The revised ACOG committee opinion on cfDNA screening for fetal aneuploidy states that a 
baseline ultrasound examination should be considered with cfDNA screening4,9. An 
ultrasound examination at the time of cfDNA screening has the potential to change prenatal 
management and prenatal genetic testing strategies, including the provider’s approach to 
counseling and the patient’s preferences and decision to select a screening or diagnostic 
test4,10–12. For instance, diagnostic testing with microarray is recommended preferentially 
over cfDNA in cases of fetal structural anomalies identified by ultrasound13,14. Despite the 
aforementioned ACOG committee opinion and the potentially important implications of 
first-trimester ultrasound examination prior to cfDNA screening, there is insufficient 
information available to determine how often ultrasound findings would result in a change in 
prenatal counseling and management. Consequently, cfDNA screening has been widely 
adopted without establishing a standardized or consistent approach to genetic screening and 
fetal ultrasound. We hypothesize that first-trimester ultrasound findings will change prenatal 
management in a clinically significant proportion of women of advanced maternal age 
(AMA).
Our main aim was to identify unexpected first-trimester ultrasound findings in a large cohort 
of AMA women to determine how frequently a first-trimester ultrasound exam gives results 
that could change a prenatal genetic testing strategy. Our second aim was to identify a 
subpopulation of patients who are candidates for cfDNA screening that are at highest risk of 
having an unanticipated abnormal ultrasound finding.
METHODS
This retrospective cohort study included all AMA women seen at a tertiary care center who 
had a first-trimester ultrasound examination. Study patients were identified via a prenatal 
diagnosis and ultrasound database. Patients included in this cohort chose a variety of testing 
options after counseling, including screening with cfDNA or traditional first-trimester 
screening of maternal serum analytes and nuchal translucency measurement, diagnostic 
testing with amniocentesis or chorionic villus sampling or no screening. cfDNA screening, 
accompanied by a first-trimester ultrasound examination, has been offered to high-risk 
women at our institution since 2012 as one option among a few testing strategies. We 
routinely offer an ultrasound exam at the time of first-trimester cfDNA screening to evaluate 
for fetal anomalies, including increased nuchal translucency (>3mm), cystic hygroma, 
multiple gestation, revision of gestational dating and viability. Cystic hygroma is defined as 
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a septate fluid-filled cavity that tends to be largest in the nuchal region but may extend along 
the length of the fetus. The study was reviewed and deemed exempt from approval by the 
University of North Carolina at Chapel Hill (UNC-CH) Institutional Review Board because 
the research involved the study of existing data and the information was recorded in such a 
way that participants could not be identified, directly or indirectly, through identifiers linked 
to them. First-trimester ultrasound examinations were performed, using Voluson E8 
ultrasound machines (GE Healthcare Ultrasound, Milwaukee, WI, USA) between 1 January 
2012 and 27 April 2015 at UNC-CH or Rex Hospital in Raleigh, NC (a UNC-CH affiliate) 
by certified sonographers in accordance with the American Institute of Ultrasound in 
Medicine Practice Guidelines for the Performance of Obstetrical Ultrasound 
Examinations15. All ultrasound examinations were interpreted by a board-certified or board-
eligible maternal-fetal medicine physician.
We searched the prenatal ultrasound database (R4; Hyland Software, Westlake, OH, USA) to 
identify all women aged ≥ 35 years who underwent a first-trimester ultrasound at 10–14 
weeks’ gestation, which is when many women typically consider prenatal genetic testing 
options, including cfDNA screening. In total, 2337 women were identified as eligible for 
inclusion in the study. Women who were not AMA and who had not had a first-trimester 
ultrasound examination were excluded. We included patients who had an ultrasound at 10–
14 weeks even if they had had a prior ultrasound, because we were interested in incidental 
findings at the time of first-trimester cfDNA screening. In the case of a single eligible 
subject having had two or more pregnancies with first-trimester ultrasound examinations 
during the inclusion period, the first pregnancy was included and any subsequent pregnancy 
was excluded to avoid information bias due to clustered data (i.e. observations from two 
different pregnancies of the same patient are not independent). From the medical records of 
each subject we abstracted information on demographics, pregnancy dating, obstetric 
ultrasound, prenatal screening, indication for ultrasound and genetic diagnostic testing. We 
used this information to determine how often first-trimester ultrasound at the time of cfDNA 
screening could change prenatal counseling and management by causing a provider to: (1) 
recommend no screening at all (i.e. non-viable pregnancy); (2) counsel more directly to 
consider diagnostic testing (i.e. fetal anomaly); (3) recommend an alternative test such as 
traditional serum screening instead of cfDNA screening (i.e. multiple gestation); or (4) delay 
ordering the screening test (i.e. if the pregnancy was not within the 9–10-week gestational-
age range at which the screening result would provide an informative result). We used 
descriptive statistics to characterize the study population and to estimate the rate of the 
primary outcome. We included women who had an ultrasound examination prior to 10 
weeks because this was an implementation study, and we were interested in incidental 
findings at the usual time of cfDNA screening for aneuploidy. We also performed a 
sensitivity analysis to estimate the rate of the primary outcome when women who had had 
an ultrasound prior to 10 weeks were excluded.
Statistical analysis
Nested within the cohort, we performed a case-control analysis to identify risk factors for 
the cohort study’s primary outcome. We defined as cases women who had an ultrasound 
finding that would have changed a prenatal genetic testing strategy and controls as those 
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with an ultrasound finding that would not have changed management. Wilcoxon, Mann-
Whitney and chi-square tests, where appropriate, were used to compare values between 
cases and controls to identify a subpopulation for which the ultrasound examination may be 
most influential. We used multivariable logistic regression analysis to estimate adjusted odds 
ratios (aORs) for identified risk factors associated with a case. The aim of this multivariable 
analysis was to identify a subpopulation of highest-risk patients who would benefit most 
from an ultrasound examination at the time of fetal aneuploidy screening. We assessed 
maternal age as a risk factor in the multivariable analysis in two different models: first as a 
continuous variable and second as a categorical variable, defined as 35–37.9 years, 38–40 
years and > 40years.
RESULTS
There were 2337 AMA women who met the inclusion criteria, with a total of 2462 fetuses. 
Among those who opted to have prenatal genetic screening (n = 1806), 68.5% had cfDNA 
screening and 31.5% had traditional first-trimester screening. All women had a 10–14-week 
ultrasound examination. Clinical and demographic characteristics of the cohort are shown in 
Table 1. Within the cohort of 2337 women, the incidence of fetal anomalies was 2.9% 
(68/2337) (Tables 2 and 3 and Figure 1). Of these 68 women, 64.7% (44/68) had diagnostic 
testing (Figure 1).
The following outcome and complication rates were estimated as they could influence 
prenatal management or screening effectiveness: 153 (6.5%) women had a non-viable 
pregnancy identified incidentally on ultrasound, consistent with a missed miscarriage. A 
multiple gestation was found incidentally in 32 (1.4%) women and five had a cotwin demise. 
Gestational dating was revised for 126 (5.4%) women. In total, 16.1% (95% CI, 15.0–
18.0%; 377/2337) had a first-trimester ultrasound finding (fetal anomaly, incorrect dating, 
multiple gestation, non-viable pregnancy) that would have altered the counseling for a 
screening or diagnostic testing strategy for fetal aneuploidy. A small subgroup of patients (n 
= 155; 6.6%) had an ultrasound scan prior to 10 gestational weeks. To assess the effect of 
having an early ultrasound, we performed a sensitivity analysis excluding these patients and 
found that 15.7% (95% CI, 15.0–18.0%; 342/2182) of women had an ultrasound finding that 
resulted in a change in prenatal genetic testing strategy or counseling at the 10–14-week 
ultrasound. Of note, 21.9% (34/155) of the women who had an ultrasound examination prior 
to 10 weeks had a subsequent unexpected finding at 10–14 weeks (anomaly or missed 
miscarriage) that would have altered the genetic counseling or prenatal screening/diagnosis 
strategy.
Of note, 35.3% (24/68) of women with a fetal anomaly on first-trimester ultrasound did not 
choose to have diagnostic testing, and 17 instead had cfDNA screening (Figure 1). Of these, 
eight (47.1%) had a negative result and nine (52.9%) had a positive result. Of those with a 
positive result, six were confirmed after birth and the remaining three resulted in miscarriage 
and the providers did not obtain confirmatory genetic testing on the products of conception. 
Of those with a negative result, five had a normal newborn examination, two were lost to 
follow-up and one had a postnatal diagnosis of a genetic syndrome, oculodentodigital 
dysplasia, confirmed by molecular testing.
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When comparing cases and controls, women with ultrasound findings that would have 
changed their management were significantly older (P = 0.04), had earlier ultrasound 
examinations (P = 0.014) and were more likely to have missing data on ethnicity (P < 0.001) 
(Table 1). Missing ethnicity data for women with an abnormal ultrasound finding is 
explained by 153/156 (98.1%) resulting in miscarriage, therefore they were classified as of 
unknown race because the genetic counselor did not meet the patient and race was not 
documented in the ultrasound database. There was no difference between cases and controls 
with regard to the rate of in-vitro fertilization (IVF) (P = 0.18). African Americans were 
least likely to have ultrasound findings that changed management compared with other 
ethnicities (Table 1). The final explanatory regression model for cases included maternal 
age, race and IVF conception. In logistic regression analysis, we found that maternal age and 
race were significantly associated with cases. In the multivariable model, cases with 
management-changing ultrasound findings were more likely to be over 40 years of age 
(aOR, 1.5 (95% CI, 1.1–2.0)) and were more likely to be Asian/Pacific Islander (aOR, 1.9 
(95% CI, 1.1–3.5)) or Hispanic (aOR, 2.9 (95% CI, 1.6–5.4)).
DISCUSSION
Initial studies on cfDNA that led to the introduction of cfDNA fetal aneuploidy screening in 
clinical practice were performed in high-risk populations as defined by ACOG4. However, 
cfDNA screening has been widely adopted in clinical practice without establishing a 
standardized approach to pretest prerequisites. In our cohort of AMA women, we observed 
that 16.1% of patients who were candidates for cfDNA screening had unexpected abnormal 
fetal ultrasound results that would impact on pretest counseling and consequently could 
impact on the screening approach. Our study highlights the importance of first-trimester 
ultrasound examination at the time of cfDNA screening.
We found that women with ultrasound findings that would change prenatal management 
were more likely to have had an earlier ultrasound and, on average, were older than women 
whose ultrasound would not have changed management. Women aged over 40 years were at 
the highest risk of having an abnormal or management-changing ultrasound finding, with a 
1.5-fold increase compared with other patients in the cohort. Other subpopulations in our 
cohort who had increased rates of abnormal or unexpected ultrasound findings were Asians 
and Hispanics. While age and ethnicity are associated with the likelihood of an abnormal 
ultrasound finding, neither factor’s association was strong enough for use in clinical 
decision-making or for clinical prediction to select a subgroup of women to target for pretest 
sonography. A previous study found differences in birth defects among ethnicities in the 
USA using a twelve-state-based birth defects tracking system16.
Among the minority of women who had an early ultrasound scan prior to 10 weeks, 22% 
were subsequently found to have a fetal anomaly or demise at the 10–14-week ultrasound, 
indicating that ultrasound before 10 weeks does not predict reliably the absence of fetal 
abnormalities that could adversely impact on cfDNA aneuploidy screening. This finding 
supports the idea of delaying sonography, if possible, or performing a second ultrasound 
examination nearer the time at which fetal aneuploidy screening is performed.
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In a recent retrospective cohort study, Reiff et al.17 described the 11–14-week ultrasound 
findings in women with negative cfDNA screening results for aneuploidy. In their cohort of 
high-risk women, unexpected ultrasound findings were seen in 3.5% of patients with a 
negative cfDNA aneuploidy screen result. Combined with the findings of Reiff et al., our 
study helps highlight the importance of first-trimester ultrasound at the time of cfDNA 
screening. However, there is an important difference between their study and ours; our study 
population included all AMA candidates eligible for cfDNA screening before a decision 
about testing was made while the study population of Reiff et al. included patients who had 
already decided to undergo screening, with a negative result. Thus, our study assesses the 
pretest utility while that of Reiff et al. assesses the post-test utility of fetal ultrasound in a 
testing strategy that employs cfDNA screening. Additionally, it is difficult to assess the 
effect of ultrasound in the implementation and performance of cfDNA screening in the 
cohort of Reiff et al. as the timing of ultrasound examination with respect to cfDNA 
screening was variable; the majority of patients had cfDNA screening prior to (18%) or on 
the day of (65%) prenatal ultrasound examination, with only 17% having the examination 
prior to cfDNA screening. Thus the two studies complement each other in estimating the 
usefulness of first-trimester ultrasound in implementing cfDNA screening. Importantly, even 
women with a negative cfDNA test result could have ultrasound findings that decrease the 
accuracy or undermine the validity of cfDNA screening.
Our study is not without limitations. The retrospective observational design allows potential 
for information or misclassification bias. However, we minimized this possibility of bias by 
using a standardized data-collection process and by validating database diagnostic and 
outcome information with electronic medical record review, including postnatal records. 
Owing to the inclusion criterion of AMA, our findings may not be generalizable to other 
low-risk populations. However, this does not invalidate our findings since they can be 
applied to the most prevalent high-risk population (AMA) currently recommended for 
cfDNA screening. There was potential for selection bias as we did not include other high-
risk populations such as women aged < 35 years at delivery with either a prior fetus with a 
trisomy, abnormal serum screening result, fetal cystic hygroma or who was a translocation 
carrier. However, these women would have a higher likelihood of having an ultrasound 
abnormality than AMA women, and bias would probably result in our study underestimating 
the clinical utility of ultrasound examination prior to genetic screening.
Our study provides important and novel information to help guide the implementation of 
fetal aneuploidy screening with cfDNA. Specifically, a considerable proportion of patients 
(16%) had a first-trimester ultrasound finding that could alter decisions about, or 
performance of, the genetic testing strategy and clinical management. Our findings indicate 
that first-trimester ultrasound provides important information in a substantial proportion of 
AMA patients eligible for cfDNA screening. The absence of a fetal ultrasound examination 
prior to cfDNA screening has the potential to increase screening costs, as well as the rate of 
duplicative screening or diagnostic testing, as a direct result of undetected abnormalities or 
errors. Prospective studies and studies assessing cost-effectiveness of an ultrasound 
examination at the time of cfDNA screening would add to our knowledge on how to employ 
optimal cfDNA screening in high-risk and general populations. However, until more data are 
available, we believe our study indicates that it is reasonable and prudent to offer a pretest 
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first-trimester ultrasound examination to all high-risk women considering cfDNA screening 
in centers in which this resource is available.
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Flowchart of screening and diagnostic choices of women of advanced maternal age after 
diagnosis of fetal anomaly on first-trimester ultrasound examination (US). cfDNA, cell-free 
DNA.
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Table 1
Clinical and demographic characteristics of women of advanced maternal age with 10–14-week ultrasound 
examination who were eligible for cell-free DNA testing for fetal aneuploidy, comparing those who had 
abnormal ultrasound findings that would have changed screening strategy and management (cases) with those 








Maternal age (years) 37.5 (36–39) 37.91 ± 2.8 37.49 ± 2.25 0.04
Ethnicity < 0.001
 Caucasian 1398 (59.8) 134 (35.5) 1264 (64.5)
 African American 243 (10.4) 19 (5.0) 224 (11.4)
 Hispanic 157 (6.7) 32 (8.5) 125 (6.4)
 Asian 153 (6.5) 20 (5.3) 133 (6.8)
 Other 108 (4.6) 16 (4.2) 92 (4.7)
 No ethnicity recorded 278 (11.9) 156 (41.4)* 122 (6.1)
In-vitro fertilization 134 (5.7) 16 (4.2) 118 (6.0) 0.18
GA at first ultrasound (weeks) 12 + 1(11 + 4 to 12 + 6) 12 + 0 ± 0.99 12 + 2 ± 1.20 0.01
Data are given as median (interquartile range), mean ± SD or n (%).
*
153/156 cases of unknown ethnicity were miscarriages; ethnicity not documented because genetic counselor did not see patient. GA, gestational 
age.













VORA et al. Page 11
Table 2
First-trimester ultrasound findings with potential to change genetic testing strategy in 2337 women of 
advanced maternal age who were eligible for cell-free DNA testing for fetal aneuploidy
Ultrasound finding n (%)
Non-viable fetus 153 (6.5)    
Revision of gestational dating 126 (5.4)    
Fetal anomaly 68 (2.9)  
Multiple gestation (new finding) 32 (1.4)  
Cotwin demise 5 (0.2)
Total 377 (16.1)*
*
There were 384 findings in 377 pregnancies.
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Table 3
Fetal anomalies identified at first-trimester ultrasound in 68 women of advanced maternal age who were 
eligible for cell-free DNA testing for fetal aneuploidy
Fetal anomaly n (%)
Cystic hygroma only 41 (60.3)
Increased NT only* 11 (16.2)
Cystic hygroma + omphalocele   7 (10.3)
Omphalocele only 3 (4.4)
Acrania/anencephaly 3 (4.4)
Cystic hygroma + limb anomaly 1 (1.5)
Cystic hygroma + cardiac anomaly 1 (1.5)
Multiple anomalies 1 (1.5)
*
Median nuchal translucency (NT), 3.3 (range, 3.0–4.5) mm.
Ultrasound Obstet Gynecol. Author manuscript; available in PMC 2017 May 17.
